<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174629</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_ES1_302</org_study_id>
    <nct_id>NCT00174629</nct_id>
  </id_info>
  <brief_title>GILT Docetaxel - Non-Small Cell Lung Cancer</brief_title>
  <official_title>Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To compare response rate between genotypic groups and control group.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To determine the safety, time to treatment failure and survival in control and genotypic&#xD;
           arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure and survival</measure>
    <time_frame>calculated from the registration date until progression or death, respectively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria.</measure>
    <time_frame>before each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel/DDP</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel/gemcitabine</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must be/have:&#xD;
&#xD;
          -  histologically confirmed non-small cell lung cancer (squamous cell carcinoma, large&#xD;
             cells or adenocarcinoma; it is recommended to provide the full paraffin-embedded block&#xD;
             or at least 5 5 sections obtained from the primary tumor, recurrence or metastasis,&#xD;
             not stained, fixed in formalin/embedded in paraffin, mounted on slides (10 micron&#xD;
             sections), as well as two serum samples in two 10-ml tubes and two blood samples (see&#xD;
             appendix X);&#xD;
&#xD;
          -  unresectable metastatic (stage IV or IIIB malignant pleural effusion) NSCLC;&#xD;
&#xD;
          -  WHO performance status &lt; 2;&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functions, assessed during the previous 14&#xD;
             days, that should be shown by the following characteristics:&#xD;
&#xD;
               -  hemoglobin &gt; or = 10g/dl and no blood cell transfusion within the previous 2&#xD;
                  weeks;&#xD;
&#xD;
               -  absolute neutrophil count &gt; 2.0 10^9 cells/l;&#xD;
&#xD;
               -  platelet count &gt; or = 100.10^9 cells/l;&#xD;
&#xD;
               -  no evidence of myelodysplastic syndrome or abnormal bone marrow reserve;&#xD;
&#xD;
               -  creatinine &lt; or = 1.5 x UNL or creatinine clearance &gt; or = 60 ml/min (real or&#xD;
                  calculated);&#xD;
&#xD;
               -  total bilirubin &lt; or = UNL;&#xD;
&#xD;
               -  ASAT (SGOT) and/or ALAT (SGPT) &lt; or = 1.5 x UNL;&#xD;
&#xD;
               -  alkaline phosphatases &lt; or = 5 x UNL;&#xD;
&#xD;
               -  serum calcium &lt; or = 1.1 x UNL;&#xD;
&#xD;
          -  at least one measurable lesion;&#xD;
&#xD;
          -  previous surgery intervention (more than 30 days before inclusion in the study) is&#xD;
             allowed but metastatic disease must be demonstrated;&#xD;
&#xD;
          -  previous radiotherapy is allowed if:&#xD;
&#xD;
               -  less or equal to 10% of bone marrow has been irradiated&#xD;
&#xD;
               -  end of radiotherapy 21 days or more prior to inclusion in the study;&#xD;
&#xD;
               -  patient has fully recovered from all toxic effects;&#xD;
&#xD;
               -  at least one of the measurable target lesions for evaluation of tumor response&#xD;
                  has not been irradiated;&#xD;
&#xD;
          -  the patient must be accessible for treatment and follow-up. The patient entered into&#xD;
             this trial must be treated and followed up at the participating center;&#xD;
&#xD;
          -  life expectancy &gt; or = 12 weeks;&#xD;
&#xD;
          -  The initial diagnostic procedures should be performed during the 4 weeks prior to the&#xD;
             randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or lactating women (women of childbearing potential must use adequate&#xD;
             contraception);&#xD;
&#xD;
          -  prior systemic chemotherapy or immunotherapy for NSCLC, even as neoadjuvant or&#xD;
             adjuvant therapy;&#xD;
&#xD;
          -  prior malignancies, except cured non-melanoma skin cancer, curatively treated in situ&#xD;
             carcinoma of the cervix or other cancer curatively treated and with non-evidence of&#xD;
             disease for at least 5 years;&#xD;
&#xD;
          -  history or clinical symptomatic brain or leptomeningeal metastases;&#xD;
&#xD;
          -  current peripheral neuropathy and neurohearing &gt; or = NCIC-CTG grade 2 except if due&#xD;
             to trauma;&#xD;
&#xD;
          -  other serious illness or medical condition, including:&#xD;
&#xD;
               -  congestive heart disease; prior myocardial infarction within 6 months;&#xD;
&#xD;
               -  history of significant neurologic or psychiatric disorders that would inhibit&#xD;
                  their understanding and giving of informed consent;&#xD;
&#xD;
               -  infection requiring I.V. antibiotics and tuberculosis under treatment ongoing at&#xD;
                  study entry;&#xD;
&#xD;
               -  untreated superior vena cava syndrome;&#xD;
&#xD;
               -  active peptic ulcer; unstable diabetes mellitus or other contraindication to high&#xD;
                  dose corticotherapy such as herpes, herpes zoster, cirrhosis;&#xD;
&#xD;
          -  hypercalcemia requiring therapy;&#xD;
&#xD;
          -  preexisting ascitis and/or clinical significant pericardial effusion;&#xD;
&#xD;
          -  patients whose lesion(s) are assessable only by radionuclide scan;&#xD;
&#xD;
          -  history of allergy to drugs containing the excipient TWEEN 80®;&#xD;
&#xD;
          -  concurrent treatment with other investigational drugs;&#xD;
&#xD;
          -  participation in a clinical trial of one or more investigational agents (i.e.&#xD;
             antibiotic) or devices within 30 days of study entry.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Aussel</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

